Cidara Therapeutics, Inc. - Laporan Laba Rugi (TTM)

Cidara Therapeutics, Inc.
US ˙ NasdaqCM ˙ US1717571079

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Cidara Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 10 12 12 41 46 50 54 28 61 23 64 62 31 23 18 13 45 1 0 0
Change (%) 18.85 -1.01 246.72 11.25 7.59 9.48 -49.10 121.87 -61.67 170.51 -1.77 -50.50 -24.67 -22.54 -26.55 237.05 -97.14 -76.31 -100.00
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 58 68 71 71 75 73 77 75 74 30 67 60 51 37 33 31 66 72 91 109
Change (%) 16.51 4.19 0.12 5.99 -2.81 5.91 -3.18 -0.62 -59.49 121.92 -9.86 -16.00 -27.48 -10.31 -6.07 114.09 8.40 25.99 20.05
% of Revenue 574.98 563.66 593.30 171.33 163.22 147.44 142.62 271.26 121.50 128.40 105.33 96.67 164.03 157.90 182.81 233.79 148.49 5,637.57 29,986.75
Gross Operating Profit -48 -56 -59 -30 -29 -24 -23 -47 -13 -7 -3 2 -20 -13 -15 -18 -22 -71 -90 -109
Change (%) 16.02 5.32 -49.87 -1.40 -19.27 -1.63 104.54 -72.14 -49.38 -49.19 -161.42 -1,050.53 -31.88 10.80 18.67 22.17 226.06 27.84 20.45
% of Revenue -474.98 -463.66 -493.30 -71.33 -63.22 -47.44 -42.62 -171.26 -21.50 -28.40 -5.33 3.33 -64.03 -57.90 -82.81 -133.79 -48.49 -5,537.57 -29,886.75
SG&A 16 16 17 17 18 19 19 19 20 15 19 18 16 14 14 15 22 21 23 25
Change (%) -1.59 4.31 2.42 5.42 4.66 2.26 -1.54 6.22 -24.02 24.75 -4.70 -13.71 -13.07 -0.42 11.57 42.54 -4.15 12.53 7.57
% of Revenue 159.13 131.76 138.84 41.01 38.86 37.80 35.31 68.29 32.69 64.81 29.89 28.99 50.54 58.33 74.98 113.89 48.16 1,616.86 7,681.46
R&D
Change (%)
% of Revenue
OpEx 75 84 87 88 93 92 97 94 95 45 86 78 66 50 46 46 88 92 108 134
Change (%) 12.59 4.22 0.56 5.88 -1.38 5.16 -2.86 0.76 -51.97 89.32 -8.72 -15.47 -24.09 -7.64 -0.94 90.65 5.33 17.03 23.49
% of Revenue 734.11 695.42 732.15 212.34 202.08 185.24 177.93 339.56 154.20 193.20 135.22 125.66 214.58 216.22 257.79 347.68 196.66 7,254.43 35,843.71
Operating Income -64 -72 -76 -47 -47 -42 -42 -66 -33 -22 -22 -16 -35 -27 -28 -33 -43 -91 -108 -134
Change (%) 11.60 5.10 -38.38 1.09 -10.16 0.09 56.48 -49.80 -34.08 2.22 -28.43 121.04 -23.58 5.17 15.30 31.54 111.35 18.34 23.83
% of Revenue -634.11 -595.42 -632.15 -112.34 -102.08 -85.24 -77.93 -239.56 -54.20 -93.20 -35.22 -25.66 -114.58 -116.22 -157.79 -247.68 -96.66 -7,154.43 -35,743.71
Interest Expense -0 -0 -0 -0 -0 -0 -0 -0 -0
Change (%) 48.86 35.11 -9.32 -17.45 -20.00 -23.58 -34.57 -68.87
% of Revenue -1.73 -2.17 -2.96 -0.78 -0.58 -0.43 -0.30 -0.38 -0.05
Net Income -64 -72 -76 -47 -47 -42 -42 -66 -33 -34 -12 -13 -37 -23 -36 -114 -121 -170 -183 -117
Change (%) 11.80 5.20 -38.25 0.96 -10.21 -0.03 56.13 -49.88 1.08 -63.41 4.11 188.24 -37.82 58.17 213.91 6.04 40.66 7.75 -35.79
% of Revenue -635.28 -597.59 -635.11 -113.11 -102.65 -85.67 -78.23 -239.94 -54.21 -142.93 -19.34 -20.49 -119.33 -98.49 -201.10 -859.41 -270.38 -13,319.76 -60,589.74

Source: Capital IQ

Other Listings
DE:20D0
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista